Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 7 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Introduction | 9 | 1 |
| Global Markets Direct Report Coverage | 9 | 1 |
| Acute Renal Failure (ARF) (Acute Kidney Injury) Overview | 10 | 1 |
| Therapeutics Development | 11 | 2 |
| Pipeline Products for Acute Renal Failure (ARF) (Acute Kidney Injury) Overview | 11 | 1 |
| Pipeline Products for Acute Renal Failure (ARF) (Acute Kidney Injury) Comparative Analysis | 12 | 1 |
| Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics under Development by Companies | 13 | 2 |
| Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics under Investigation by Universities/Institutes | 15 | 1 |
| Acute Renal Failure (ARF) (Acute Kidney Injury) Pipeline Products Glance | 16 | 4 |
| Late Stage Products | 16 | 1 |
| Clinical Stage Products | 17 | 1 |
| Early Stage Products | 18 | 1 |
| Unknown Stage Products | 19 | 1 |
| Acute Renal Failure (ARF) (Acute Kidney Injury) Products under Development by Companies | 20 | 2 |
| Acute Renal Failure (ARF) (Acute Kidney Injury) Products under Investigation by Universities/Institutes | 22 | 1 |
| Acute Renal Failure (ARF) (Acute Kidney Injury) Companies Involved in Therapeutics Development | 23 | 26 |
| A1M Pharma AB | 23 | 1 |
| Adrenomed AG | 24 | 1 |
| Am-Pharma B.V. | 25 | 1 |
| Angion Biomedica Corp. | 26 | 1 |
| Atox Bio Ltd. | 27 | 1 |
| Cellmid Limited | 28 | 1 |
| Complexa, Inc. | 29 | 1 |
| DiaMedica Inc. | 30 | 1 |
| Digna Biotech, S.L. | 31 | 1 |
| DURECT Corporation | 32 | 1 |
| F. Hoffmann-La Roche Ltd. | 33 | 1 |
| G1 Therapeutics, Inc. | 34 | 1 |
| Kringle Pharma, Inc. | 35 | 1 |
| NephroGenex, Inc. | 36 | 1 |
| NeuroVive Pharmaceutical AB | 37 | 1 |
| Noorik Biopharmaceuticals AG | 38 | 1 |
| Noxxon Pharma AG | 39 | 1 |
| Orion Oyj | 40 | 1 |
| ProMetic Life Sciences Inc. | 41 | 1 |
| Quark Pharmaceuticals, Inc. | 42 | 1 |
| SBI Pharmaceuticals Co., Ltd. | 43 | 1 |
| Spherium Biomed S.L. | 44 | 1 |
| STATegics, Inc. | 45 | 1 |
| Stealth BioTherapeutics Inc. | 46 | 1 |
| Thrasos Therapeutics Inc. | 47 | 1 |
| Torrent Pharmaceuticals Limited | 48 | 1 |
| Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics Assessment | 49 | 10 |
| Assessment by Monotherapy Products | 49 | 1 |
| Assessment by Combination Products | 50 | 1 |
| Assessment by Target | 51 | 2 |
| Assessment by Mechanism of Action | 53 | 2 |
| Assessment by Route of Administration | 55 | 2 |
| Assessment by Molecule Type | 57 | 2 |
| Drug Profiles | 59 | 69 |
| (aminolevulinic acid hydrochloride + sodium ferrous citrate) Drug Profile | 59 | 1 |
| A1M-001 Drug Profile | 60 | 1 |
| AB-103 Drug Profile | 61 | 3 |
| adrecizumab Drug Profile | 64 | 1 |
| BB-3 Drug Profile | 65 | 4 |
| CAB-101 Drug Profile | 69 | 1 |
| Cardiotrophin-1 Drug Profile | 70 | 2 |
| CXA-10 Drug Profile | 72 | 2 |
| cyclosporine Drug Profile | 74 | 5 |
| DM-199 Drug Profile | 79 | 4 |
| DUR-928 Drug Profile | 83 | 2 |
| elamipretide Drug Profile | 85 | 7 |
| HYPER-IL-6 Drug Profile | 92 | 1 |
| KP-100IT Drug Profile | 93 | 2 |
| levosimendan Drug Profile | 95 | 4 |
| MG-53 Drug Profile | 99 | 2 |
| MIX-9 Drug Profile | 101 | 1 |
| N-003 Drug Profile | 102 | 1 |
| NOXD-21 Drug Profile | 103 | 1 |
| PBI-4419 Drug Profile | 104 | 1 |
| Pyridoxamine Dihydrochloride Drug Profile | 105 | 4 |
| QPI-1002 Drug Profile | 109 | 3 |
| R-190 Drug Profile | 112 | 2 |
| Recombinant Human Alkaline Phosphatase Replacement for Ulcerative Colitis, Acute Renal Failure, Sepsis and Hypophosphatasia Drug Profile | 114 | 3 |
| Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis Drug Profile | 117 | 1 |
| RLS-003 Drug Profile | 118 | 1 |
| RO-6839328 Drug Profile | 119 | 1 |
| Small Molecule to Inhibit CDK4 and CDK6 for Acute Kidney Injury and Breast Cancer Drug Profile | 120 | 1 |
| Small Molecule to Inhibit HDAC for Acute Kidney Injury Drug Profile | 121 | 1 |
| SP-15016 Drug Profile | 122 | 1 |
| STSE-15 Drug Profile | 123 | 2 |
| THR-184 Drug Profile | 125 | 2 |
| TRC-160334 Drug Profile | 127 | 1 |
| Acute Renal Failure (ARF) (Acute Kidney Injury) Dormant Projects | 128 | 1 |
| Acute Renal Failure (ARF) (Acute Kidney Injury) Discontinued Products | 129 | 1 |
| Acute Renal Failure (ARF) (Acute Kidney Injury) Product Development Milestones | 130 | 10 |
| Featured News &Press Releases | 130 | 1 |
| Jun 07, 2016: NeuroVive announces CiPRICS study completes enrolment | 130 | 1 |
| May 10, 2016: AM-Pharma publishes safety and pharmacokinetic data from Phase I recAP trial | 131 | 1 |
| Apr 26, 2016: AM-Pharma receives FDA fast track designation for recAP in Acute Kidney Injury | 131 | 1 |
| Mar 14, 2016: NeuroVive announces the CiPRICS study enrols 100 patients and reports favourable safety evaluation | 132 | 1 |
| Mar 14, 2016: Quark Pharmaceuticals Doses First Patient In Two Pivotal Clinical Studies of RNAi-Based Therapeutic QPI-1002 | 132 | 1 |
| Feb 29, 2016: Thrasos Announces Promising Results for Phase II THR-184 Dose Ranging Clinical Study for the Prevention of Acute Kidney Injury (AKI) | 133 | 1 |
| Jan 06, 2016: DURECT Announces Positive Phase 1 Data for DUR-928 | 133 | 1 |
| Dec 14, 2015: NephroGenex Announces FDA Clearance Of IND Application For Clinical Study Of Intravenous Pyridorin In The Treatment Of Acute Kidney Injury | 134 | 1 |
| Nov 19, 2015: NeuroVive reports favourable safety evaluation in Phase II acute kidney injury study | 135 | 1 |
| Nov 10, 2015: Thrasos Strengthens Composition of Matter Coverage on THR-184 with Japanese Patent Decision | 135 | 1 |
| Nov 04, 2015: DiaMedica Provides Corporate Update | 136 | 1 |
| Nov 04, 2015: NephroGenex Announces Successful Results from Toxicity Study of Intravenous Pyridorin | 137 | 1 |
| Nov 02, 2015: Angion Biomedica to Present Clinical and Preclinical Data at the Upcoming American Society of Nephrology Conference in San Diego | 137 | 1 |
| Oct 30, 2015: Licensee's drug to commence Phase 2 and Phase 3 trials | 138 | 1 |
| Jul 07, 2015: Thrasos Completes Enrollment of Phase 2 THR-184 Clinical Study for Acute Kidney Injury | 138 | 2 |
| Appendix | 140 | 2 |
| Methodology | 140 | 1 |
| Coverage | 140 | 1 |
| Secondary Research | 140 | 1 |
| Primary Research | 140 | 1 |
| Expert Panel Validation | 140 | 1 |
| Contact Us | 140 | 1 |
| Disclaimer | 141 | 1 |